ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

被引：2709

作者：

Van Cutsem, E. ^{[1
,2
]}

Cervantes, A. ^{[3
]}

Adam, R. ^{[4
]}

Sobrero, A. ^{[5
]}

Van Krieken, J. H. ^{[6
]}

Aderka, D. ^{[7
]}

Aranda Aguilar, E. ^{[8
]}

Bardelli, A. ^{[9
]}

Benson, A. ^{[10
]}

Bodoky, G. ^{[11
]}

Ciardiello, F. ^{[12
]}

D'Hoore, A. ^{[2
,13
]}

Diaz-Rubio, E. ^{[14
]}

Douillard, J. -Y. ^{[15
]}

Ducreux, M. ^{[16
]}

Falcone, A. ^{[17
,18
]}

Grothey, A. ^{[19
]}

Gruenberger, T. ^{[20
]}

Haustermans, K. ^{[2
,21
]}

Heinemann, V. ^{[22
]}

Hoff, P. ^{[23
]}

Koehne, C. -H. ^{[24
]}

Labianca, R. ^{[25
]}

Laurent-Puig, P. ^{[26
]}

Ma, B. ^{[27
]}

Maughan, T. ^{[28
]}

Muro, K. ^{[29
,30
]}

Normanno, N. ^{[31
]}

Osterlund, P. ^{[32
,33
]}

Oyen, W. J. G. ^{[34
,35
]}

Papamichael, D. ^{[36
]}

Pentheroudakis, G. ^{[37
]}

Pfeiffer, P. ^{[38
]}

Price, T. J. ^{[39
]}

Punt, C. ^{[40
]}

Ricke, J. ^{[41
]}

Roth, A. ^{[42
]}

Salazar, R. ^{[43
]}

Scheithauer, W. ^{[44
,45
]}

Schmoll, H. J. ^{[46
]}

Tabernero, J. ^{[47
]}

Taieb, J. ^{[26
]}

Tejpar, S. ^{[1
,2
]}

Wasan, H. ^{[48
]}

Yoshino, T. ^{[49
]}

Zaanan, A. ^{[26
]}

Arnold, D. ^{[50
]}

机构：

[1] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium

[2] Katholieke Univ Leuven, Leuven, Belgium

[3] Univ Valencia, INCLIVA, Med Oncol Dept, Valencia, Spain

[4] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France

[5] IRCCS San Martino Hosp, Med Oncol, Genoa, Italy

[6] Radboud Univ Nijmegen, Med Ctr, Oncol Res Inst, Nijmegen, Netherlands

[7] Tel Aviv Univ, Sheba Med Ctr, Div Oncol, Tel Aviv, Israel

[8] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain

[9] Univ Turin, Sch Med, Turin, Italy

[10] Northwestern Med Grp, Div Hematol Oncol, Chicago, IL USA

[11] St Laszlo Hosp, Dept Oncol, Budapest, Hungary

[12] Univ Naples 2, Div Med Oncol, Naples, Italy

[13] Univ Hosp Gasthuisberg Leuven, Abdominal Surg, Leuven, Belgium

[14] Hosp Clin San Carlos, Dept Med Oncol, Madrid, Spain

[15] ICO, Med Oncol, St Herblain, France

[16] Univ Paris Saclay, Gustave Roussy, Dept Med Oncol, Villejuif, France

[17] Univ Pisa, Dept Med Oncol, Pisa, Italy

[18] Ist Toscano Tumori, Univ Hosp S Chiara, Dept Oncol, Div Med Oncol, Pisa, Italy

[19] Mayo Clin, Div Med Oncol, Rochester, MN USA

[20] Rudolfstiftung Hosp, Dept Surg 1, Vienna, Austria

[21] Univ Hosp Gasthuisberg, Dept Radiat Oncol, Leuven, Belgium

[22] Univ Clin Munich, Ctr Comprehens Canc, Munich, Germany

[23] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[24] Univ Campus Klinikum Oldenburg, Northwest German Canc Ctr, Oldenburg, Germany

[25] Osped Giovanni 23, Ctr Canc, Bergamo, Italy

[26] Hop Europeen Georges Pompidou, Digest Oncol Dept, Paris, France

[27] Chinese Univ Hong Kong, State Key Lab Oncol South China, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[28] Univ Oxford, Gray Labs, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England

[29] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[30] Aichi Canc Ctr Hosp, Outpatient Treatment Ctr, Nagoya, Aichi, Japan

[31] INT Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy

[32] Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland

[33] Univ Helsinki, Dept Oncol, Helsinki, Finland

[34] Inst Canc Res, London, England

[35] Royal Marsden Hosp, London, England

[36] Bank Cyprus Oncol Ctr, Dept Med Oncol, Nicosia, Cyprus

[37] Univ Ioannina, Dept Med Oncol, Ioannina, Greece

[38] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[39] Queen Elizabeth Hosp, Haematol & Med Oncol Unit, Woodville, SA, Australia

[40] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands

[41] Univ Clin Magdeburg, Dept Radiol & Nucl Med, Magdeburg, Germany

[42] HUG, Digest Tumors Unit, Geneva, Switzerland

[43] ICO, Barcelona, Spain

[44] Med Univ Vienna, Dept Internal Med, Vienna, Austria

[45] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria

[46] Univ Halle Wittenberg, Univ Clin Halle, Dept Internal Med 4, Halle, Germany

[47] VHIO, Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[48] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Canc Med, London, England

[49] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan

[50] ICO, Lisbon, Portugal

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 08期

关键词：

colorectal cancer; ESMO; consensus; clinical practice guidelines; RANDOMIZED PHASE-III; STEREOTACTIC BODY RADIOTHERAPY; CETUXIMAB PLUS IRINOTECAN; CIRCULATING TUMOR DNA; ANTI-EGFR THERAPY; WILD-TYPE KRAS; K-RAS MUTATIONS; PERITONEAL SURFACE MALIGNANCIES; OXALIPLATIN-BASED CHEMOTHERAPY; UNRESECTABLE LIVER METASTASES;

D O I：

10.1093/annonc/mdw235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical outcome for patients with metastatic CRC (mCRC) has improved greatly over the last 20 years. These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

引用

页码：1386 / 1422

页数：37

共 303 条

[1]

Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16

[2] Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases [J].

Adam, R. ;

Barroso, E. ;

Laurent, C. ;

Nuzzo, G. ;

Hubert, C. ;

Mentha, G. ;

Ijzermans, J. ;

Capussotti, L. ;

Lopezben, S. ;

Mirza, D. ;

Kaiser, G. ;

Oussoultzoglou, E. ;

Gruenberger, T. ;

Poston, G. J. ;

Skipenko, O. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[3] The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus [J].

Adam, Rene ;

De Gramont, Aimery ;

Figueras, Joan ;

Guthrie, Ashley ;

Kokudo, Norihiro ;

Kunstlinger, Francis ;

Loyer, Evelyne ;

Poston, Graeme ;

Rougier, Philippe ;

Rubbia-Brandt, Laura ;

Sobrero, Alberto ;

Tabernero, Josep ;

Teh, Catherine ;

Van Cutsem, Eric .

ONCOLOGIST, 2012, 17 (10) :1225-1239

[4] Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? [J].

Adam, Rene ;

Bhangui, Prashant ;

Poston, Graeme ;

Mirza, Darius ;

Nuzzo, Gennaro ;

Barroso, Eduardo ;

Ijzermans, Jan ;

Hubert, Catherine ;

Ruers, Theo ;

Capussotti, Lorenzo ;

Ouellet, Jean-Francois ;

Laurent, Christophe ;

Cugat, Esteban ;

Colombo, Pierre Emmanuel ;

Milicevic, Miroslav .

ANNALS OF SURGERY, 2010, 252 (05) :774-785

[5] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].

Adams, Richard A. ;

Meade, Angela M. ;

Seymour, Matthew T. ;

Wilson, Richard H. ;

Madi, Ayman ;

Fisher, David ;

Kenny, Sarah L. ;

Kay, Edward ;

Hodgkinson, Elizabeth ;

Pope, Malcolm ;

Rogers, Penny ;

Wasan, Harpreet ;

Falk, Stephen ;

Gollins, Simon ;

Hickish, Tamas ;

Bessell, Eric M. ;

Propper, David ;

Kennedy, M. John ;

Kaplan, Richard ;

Maughan, Timothy S. .

LANCET ONCOLOGY, 2011, 12 (07) :642-653

[6]

Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO

[7]

2-M

[8] Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations [J].

Albanese, I ;

Scibetta, AG ;

Migliavacca, M ;

Russo, A ;

Bazan, V ;

Tomasino, RM ;

Colomba, P ;

Tagliavia, M ;

La Farina, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 325 (03) :784-791

[9]

Alfonso P Garcia, 2014, ANN ONCOL S4, V25

[10] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

← 1 2 3 4 5 6 7 8 9 10 →